ACTRN12613001138774招募中不适用
A multi-centre, double blind (outcome assessor and participant), randomised, controlled trial comparing the efficacy of manual acupuncture to inactive control sham laser for the treatment of chronic (greater than 3 months) lateral elbow pain.
niversity of Technology, Sydney0 个研究点目标入组 96 人开始时间: 2013年10月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •Chronic lateral elbow pain (duration greater than 3 months)
- •Unilateral localisation
排除标准
- •1. Diseases of the central or peripheral nervous system
- •2. Inflammatory rheumatic diseases
- •4. Earlier episodes of lateral elbow pain treated surgically
- •- acupuncture treatment or physiotherapy for tennis
- •elbow within the previous 3 months
- •- acupuncture treatment for any problems within the
- •previous week
- •- concurrent physiotherapy for tennis elbow.
研究者
相似试验
进行中（未招募）
不适用
A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated idraparinux (SSR126517E) with oral adjusted-dose warfarin in the prevention of stroke and systemic thromboembolic events in patients with atrial fibrillation - BOREALIS-AFThe subjects who will participate to this clinical trial are not healthy volonteers.They have Permanent, persistent or paroxysmal non-valvular atrial fibrillation that is ECG-documented, with an indication for long-term VKA therapy.EUCTR2007-004817-33-PTsanofi-aventis recherche&développement9,600
Unknown
3 期
A clinical trial to study the safety and efficacy of a new drug biotinylated idraparinux (SSR126517E) as compared to another drug warfarin in the prevention of stroke and systemic thromboembolic events in patients with atrial fibrillatioCTRI/2008/091/000018SanofiSynthelabo India Limited9,600
进行中（未招募）
不适用
A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated idraparinux (SSR126517E) with oral adjusted-dose warfarin in the prevention of stroke and systemic thromboembolic events in patients with atrial fibrillation - BOREALIS-AFEUCTR2007-004817-33-GRsanofi-aventis recherche&développement9,600
已完成
不适用
A clinical trial to study the safety and efficacy of a new drug biotinylated idraparinux (SSR126517E) as compared to another drug warfarin in the prevention of stroke and systemic thromboembolic events in patients with atrial fibrillatio-I48 Atrial fibrillation and flutterAtrial fibrillation and flutterI48PER-067-08sanofi-aventis Recherche & Development,
进行中（未招募）
不适用
A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated idraparinux (SSR126517E) with oral adjusted-dose warfarin in the prevention of stroke and systemic thromboembolic events in patients with atrial fibrillation - BOREALIS-AFEUCTR2007-004817-33-SKsanofi-aventis recherche&développement9,600